May 8, 2026
Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn
Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its focus on brain health and rare diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







